ReviewInternational journal of colorectal disease2021
Visceral adiposity and inflammatory bowel disease.
Review in International journal of colorectal disease, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 1 synthesis or guideline pooled it, 52 citations in OpenAlex.
- Nutrition, Nutritional Status, Micronutrients Deficiency, and Disease Course of Inflammatory Bowel Disease.Nutrients · 2023Pooled it
- Beyond Inflammation - A Multidisciplinary Approach to Managing Obesity and Cardiometabolic Risk in Inflammatory Bowel Disease.Current diabetes reports · 2026Review
- Obesity: An Overlooked Factor in Inflammatory Bowel Disease.International journal of molecular sciences · 2026Review
- The CT-based attenuation index of peri-bowel adipose tissue can predict disease progression in inflammatory bowel disease patients.European radiology · 2026Article
- Factors associated with clinical outcomes of breast cancer based on glucose metabolic activity of subcutaneous adipose tissue.Frontiers in oncology · 2026Article
- Obesity impairs gut repair via AFABP-mediated iron overload in intestinal stem cells.Nature metabolism · 2026Article
- Glucagon like peptide 1 receptor agonists in patients with inflammatory bowel disease: safety, clinical effectiveness and anti-inflammatory mechanisms.Frontiers in gastroenterology (Lausanne, Switzerland) · 2026Review
- A risk assessment model for colon cancer and precancerous lesions based on cancer screening and external validation of the NHANES database.Frontiers in oncology · 2026Article
- Chemerin and the Gut: From Inflammation to Cancer.Biomedicines · 2025Review
- Galectin-3-Insights from Inflammatory Bowel Disease and Primary Sclerosing Cholangitis.International journal of molecular sciences · 2025Review
- Association of regional adiposity distribution with risk of autoimmune diseases.Clinical rheumatology · 2025Article
- Increased CT Attenuation of Pericolic Adipose Tissue as a Noninvasive Marker of Disease Severity in Ulcerative Colitis.Korean journal of radiology · 2025Article
- Potential Therapeutic Exploitation of G Protein-Coupled Receptor 120 (GPR120/FFAR4) Signaling in Obesity-Related Metabolic Disorders.International journal of molecular sciences · 2025Review
- Associations between sugar-sweetened beverage consumption, weight-adjusted-waist index, with psychological symptoms: a cross-sectional survey of adolescents in mainland China.Frontiers in psychiatry · 2025Article
- Association Between Visceral Adipose Tissue and Chronic Respiratory Diseases: A Two-Sample Multivariable Mendelian Randomization Study in European Population.International journal of chronic obstructive pulmonary disease · 2025Article
- MARVELD1 as a tumor stem cell marker and therapeutic target in visceral obesity-associated ovarian cancer.American journal of cancer research · 2025Article
- Impact of oral pathogens on inflammatory mediator expression in oral cells.Bioinformation · 2025Article
- Impact of Obesity on the Long-Term Outcomes of Advanced Therapies in IBD: A Real-World Study in Taiwan.Journal of inflammation research · 2025Article
- Gut microbiota and mesenteric adipose tissue interactions in shaping phenotypes and treatment strategies for Crohn's disease.World journal of gastroenterology · 2024Article
- Impact of body mass index on the efficacy of treatment modalities in women with refractory overactive bladder.Scientific reports · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRates of obesity are increasing worldwide, as is the incidence of inflammatory bowel disease (IBD). Obesity is now considered an inflammatory state. Visceral adiposity in particular may be associated with a more severe inflammatory phenotype in IBD.
aimThe aim of this review article is to summarise the current literature on the association between visceral adiposity and outcomes in inflammatory bowel disease
methodsTo collect relevant articles, PubMed/MEDLINE and Embase searches were performed using Boolean search phrases. Grey literature and manual searches were also performed. Abstracts were selected by two independent reviewers based on pre-determined criteria. Full text articles were reviewed, and data extracted and assessed.
resultsOne hundred twenty-seven abstracts were obtained through the initial search, with 85 abstracts reviewed and 22 full text articles included. Characteristics are included in Table 1. Most of these were retrospective studies and of moderate or weak quality. Studies suggested visceral fat content is higher in Crohn's disease than in healthy controls. Visceral adiposity was associated with an increased risk of complex Crohn's disease phenotype (OR 26.1 95% CI 2-75.4; p = 0.02). Post-operative recurrence was higher in patients with higher visceral fat indices (RR 2.1; CI 1.5-3; p = 0.012). There were conflicting data regarding the effect of visceral adiposity on post-operative complications and the efficacy of medical therapy. Table 1 Study characteristics Author Year Country Study type Study numbers Control group Disease type Methodology e.g. CT Body composition measurements Results Argeny [24] 2018 Austria Retrospective cohort N = 95 N/A Crohn's disease CT; L3 level Visceral fat area (cm
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.